The question of the use of Andexxa, a reversal agent for Factor Xa Inhibitors, has been batting around my brain for a few months now. We are in the unfortunate position of having a drug with very questionable evidentiary support but with an FDA labelled indication. I received an email from the lead author of paper just published in Neurocritical Care.
- Peled et al. Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 10.1007/s12028-019-00866-6
Dr. Harry Peled is the medical director of Cardiology and Critical Care at St Jude Medical Center in California. Relevantly, he is also chair of the Pharmacy an Therapeutics Committee.
I would love to hear your thoughts on this issue–place them in the comments below.
See Also
Now on to the Podcast…
Podcast: Play in new window | Download (Duration: 19:00 — 17.8MB) | Embed
Subscribe: Apple Podcasts | Android | Google Podcasts | Spotify | RSS | More
- EMCrit 278 – Labors of Trauma – Blunt Edition (Part 1) - July 24, 2020
- EMCrit 277 – COVID Pulmonary Physiology with Martin Tobin - July 9, 2020
- EMCrit 276 – The Rapid Code Status Conversation with Kei Ouchi - June 25, 2020